CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered for extended stability in circulation compared to native GHRH.
🔬 Studied for: GHRH-Pathway Research
💊 Also studied for: Combination Protocol Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered for extended stability in circulation compared to native GHRH. The version most commonly referenced in research without the DAC (drug affinity complex) modifier is closer in half-life to native GHRH and is frequently studied in combination with GH secretagogues like Ipamorelin.
CJC-1295 binds GHRH receptors in the anterior pituitary, stimulating synthesis and release of growth hormone. Research has focused on its modified amino-acid sequence, which confers resistance to enzymatic degradation and produces a more sustained GHRH signal than native GHRH in preclinical models.
These are effects CJC-1295 (No DAC) has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
CJC-1295 is a frequent subject of research examining GHRH receptor signaling and its downstream effects on pulsatile GH and IGF-1 output, often in comparative studies against other GHRH analogs.
Because GHRH analogs and ghrelin-receptor agonists act on distinct receptors upstream of GH release, CJC-1295 is frequently studied alongside secretagogues such as Ipamorelin to examine potential synergistic effects on GH pulse amplitude.
Doses used in preclinical and small clinical research studies vary by study design and are not established as a standardized human protocol. No FDA-approved human dosage exists for CJC-1295.
Compound X does not provide dosing recommendations. CJC-1295 (No DAC) is sold for laboratory research use only and is not intended for human consumption.
CJC-1295 is not FDA-approved for human use and has not completed large-scale controlled human trials. Reported concerns in available literature and anecdotal reports include injection-site reactions and, due to its GH-axis activity, theoretical concerns about insulin sensitivity that have not been fully characterized in long-term human data.
No. CJC-1295 (No DAC) is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
GHRH-Pathway Research — CJC-1295 is a frequent subject of research examining GHRH receptor signaling and its downstream effects on pulsatile GH and IGF-1 output, often in comparative studies against other GHRH analogs.
In the US, UK, Canada and Australia, CJC-1295 (No DAC) is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
CJC-1295 research is indexed on PubMed under search terms such as "CJC-1295 GHRH analog" and "growth hormone releasing hormone modified peptide."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.